Inflammatory disease biotech company Rezera (RZRA.US) postpones its US$200 million US IPO.
Biotech company Rezera said last Thursday that it will postpone its listing.
Rezera (RZRA.US), a biotech company developing oral NLRP3 inflammatory inhibitors with a pipeline that has advanced to Phase III clinical trials, said last Thursday that it will postpone its listing. The company had previously filed for an IPO, planning to offer 16.7 million shares at a price range of US$1113, to raise US$200 million. Pharmaceutical company GlaxoSmithKline plc Sponsored ADR (GSK.US), as a new investor together with its affiliates, committed to subscribe for up to US$25 million, accounting for 13% of the offering size.
The Boston, Massachusetts-based company was founded in 2016 and had planned to list on Nasdaq under the ticker RZRA. Jefferies Financial Group Inc., TD Securities, and Cantor Fitzgerald are serving as joint bookrunners for the IPO.
Related Articles
.png)
Amid a sharp U.S. stock market selloff, the parent company of "GTA 6" bucked the trend and closed higher! First-day sales of US$3.79 billion set a record, and Wall Street's focus shifted to the next-generation GTA Online.

HK Bull/Bear Outstanding Qty Ratio(48:52) | November 21

NVIDIA Corporation (NVDA.US) has plunged 46% over seven weeks, marking its longest losing streak since the 2008 financial crisis, with US$2.6 trillion in market value wiped out.
Amid a sharp U.S. stock market selloff, the parent company of "GTA 6" bucked the trend and closed higher! First-day sales of US$3.79 billion set a record, and Wall Street's focus shifted to the next-generation GTA Online.
.png)
HK Bull/Bear Outstanding Qty Ratio(48:52) | November 21

NVIDIA Corporation (NVDA.US) has plunged 46% over seven weeks, marking its longest losing streak since the 2008 financial crisis, with US$2.6 trillion in market value wiped out.






